| Product NDC: | 0597-0003 |
| Proprietary Name: | Aptivus |
| Non Proprietary Name: | tipranavir |
| Active Ingredient(s): | 250 mg/1 & nbsp; tipranavir |
| Administration Route(s): | ORAL |
| Dosage Form(s): | CAPSULE, LIQUID FILLED |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 0597-0003 |
| Labeler Name: | Boehringer Ingelheim Pharmaceuticals, Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA021814 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20050701 |
| Package NDC: | 0597-0003-02 |
| Package Description: | 1 BOTTLE, PLASTIC in 1 CARTON (0597-0003-02) > 120 CAPSULE, LIQUID FILLED in 1 BOTTLE, PLASTIC |
| NDC Code | 0597-0003-02 |
| Proprietary Name | Aptivus |
| Package Description | 1 BOTTLE, PLASTIC in 1 CARTON (0597-0003-02) > 120 CAPSULE, LIQUID FILLED in 1 BOTTLE, PLASTIC |
| Product NDC | 0597-0003 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | tipranavir |
| Dosage Form Name | CAPSULE, LIQUID FILLED |
| Route Name | ORAL |
| Start Marketing Date | 20050701 |
| Marketing Category Name | NDA |
| Labeler Name | Boehringer Ingelheim Pharmaceuticals, Inc. |
| Substance Name | TIPRANAVIR |
| Strength Number | 250 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | HIV Protease Inhibitors [MoA],Protease Inhibitor [EPC] |